Trial Profile
Pembrolizumab in Patients With Leptomeningeal Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Meningeal carcinomatosis
- Focus Therapeutic Use
- 31 May 2020 Status changed from recruiting to discontinued, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 09 Dec 2019 Status changed from recruiting to completed.